Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Other Working Capital Changes (2019 - 2025)

Summit Therapeutics (SMMT) has disclosed Other Working Capital Changes for 7 consecutive years, with -$2000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Working Capital Changes rose 99.92% year-over-year to -$2000.0, compared with a TTM value of $80000.0 through Dec 2025, up 103.24%, and an annual FY2025 reading of $80000.0, up 103.24% over the prior year.
  • Other Working Capital Changes was -$2000.0 for Q4 2025 at Summit Therapeutics, down from $30000.0 in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $3.6 million in Q3 2023 and bottomed at -$4.5 million in Q2 2022.
  • Average Other Working Capital Changes over 5 years is -$352833.3, with a median of $26000.0 recorded in 2025.
  • Peak annual rise in Other Working Capital Changes hit 248.39% in 2022, while the deepest fall reached 4693.88% in 2022.
  • Year by year, Other Working Capital Changes stood at -$186000.0 in 2021, then surged by 248.39% to $276000.0 in 2022, then tumbled by 148.19% to -$133000.0 in 2023, then tumbled by 1809.77% to -$2.5 million in 2024, then skyrocketed by 99.92% to -$2000.0 in 2025.
  • Business Quant data shows Other Working Capital Changes for SMMT at -$2000.0 in Q4 2025, $30000.0 in Q3 2025, and $27000.0 in Q2 2025.